1. Home
  2. Directory
  3. Massachusetts
  4. Attleboro
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1477040558

DR. TZU-YING CHUANG MD, PHD
Prescription History 1477040558
Psychiatry & Neurology - Neurology in Attleboro, MA

NPI Status: Active since April 16, 2018

Contact Information

211 PARK ST
ATTLEBORO, MA
ZIP 02703
Phone: (508) 222-5200
Fax: (508) 236-7335

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TZU-YING CHUANG MD, PHD, an active Neurology specialist practicing in Attleboro, MA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 84 documented patient claims. Among these therapy options, the most frequently utilized medication is Baclofen, which accounts for 27 claims alone.

Medication Index

B
G
K
T
No matching medications currently found on file.

Baclofen

Generic Formulation: BaclofenSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 27
30-Day Fills 43.0
Days Supply 1,260
MA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,289
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $778.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.84

State Avg Cost Per Claim

$34.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Therapeutic Applications

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Gabapentin

Generic Formulation: GabapentinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
MA State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills111.6
Peer Average Days Supply3,206
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.9% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.77

State Avg Cost Per Claim

$20.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Glatiramer Acetate

Generic Formulation: Glatiramer AcetateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 14.6
Days Supply 420
MA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply544
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,847.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,986.09

State Avg Cost Per Claim

$4,003.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Therapeutic Applications

This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

Kesimpta Pen

Generic Formulation: OfatumumabSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
MA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,302
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.4% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $145,104.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,673.62

State Avg Cost Per Claim

$10,140.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ofatumumab is used to treat a certain type of cancer (chronic lymphocytic leukemia - CLL). Ofatumumab belongs to a class of drugs known as monoclonal antibodies. This medication works by stopping the growth of cancer cells.

Teriflunomide

Generic Formulation: TeriflunomideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
MA State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$47.22

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used by adults to treat multiple sclerosis-MS. It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in your brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TZU-YING CHUANG MD, PHD provides transparency into local medical care patterns within Attleboro, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.